Drug firm Strides Acrolab today said that it has received American health regulator Food and Drug Administration's (FDA) nod for marketing and distributing Bacitracin injections, an anti-infective used to treat pneumonia, in the US.
The company, in a filing to the Bombay Stock Exchange, said that the FDA's nod for Bacitracin injections is the seventh sterile injectables approval received by the company in the current year.
According to the market research firm IMS, the total US market for the drug is around $32 million. Strides expects the launch to happen by the third quarter of 2010.
The company will introduce the drug in the US market through Sagent Pharmaceuticals, with which Strides had signed a pact for developing and supplying more than 25 injectables.
Under the 2007 pact, Strides was required to develop and supply 25 injectables, which would then be marketed in the US by Sagent.
